The improved vaccine has already been approved by the United Arab Emirates as a booster shot and enhances immune response to the coronavirus, the company said in December.
China National Pharmaceutical Group Co. said its second-generation recombinant protein Covid-19 vaccine has received approval from Beijing for clinical trials.
Better known as Sinopharm, the state-owned enterprise’s vaccine-developing unit, China National Biotec Group, announced the news on its WeChat account on Sunday.
